Testosterone treatment in middle-aged and older men with hypogonadism was found to significantly increase the risk of clinical fractures, according to a recent analysis. The study, which involved over 5000 men, found that the testosterone group had a 43% increased risk for clinical fractures compared to the placebo group. The most common fracture sites were ribs, wrist, and ankle, which are associated with low bone mineral density and increased mortality. The unexpected results suggest that the potential benefits of testosterone treatment should be carefully weighed against the risk of fractures. The study was supported by several pharmaceutical companies.
Source link
Testosterone Treatment for Hypogonadism Does Not Lower Fracture Risk
